of its "massive" and semi-massive" sulphides on it's website, so the shareholders got all juiced up thinking it was going to be the next Noront. Their actual assay percentages were nowhere near the expectations, thus the punishment by way of share price.

Sage is not promoting itself in that fashion, so I don't believe it will demonstrate  the same effects in share price.

JMHO